JP4717633B2 - 癌関連タンパク質を標的とするＲＮＡｉプローブ - Google Patents

癌関連タンパク質を標的とするＲＮＡｉプローブ Download PDF

Info

Publication number
JP4717633B2
JP4717633B2 JP2005501198A JP2005501198A JP4717633B2 JP 4717633 B2 JP4717633 B2 JP 4717633B2 JP 2005501198 A JP2005501198 A JP 2005501198A JP 2005501198 A JP2005501198 A JP 2005501198A JP 4717633 B2 JP4717633 B2 JP 4717633B2
Authority
JP
Japan
Prior art keywords
seq
cells
clu
sirna
clusterin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2005501198A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006500958A5 (enExample
JP2006500958A (ja
Inventor
ヤンセン、バークハード
グリーブ、マーティン、イー．
シグナエブスキー、マクシム
ベラルディ、エリアナ
トルガコス、イオアニス、ピー．
ゴノス、エフスタシオス、エス．
Original Assignee
ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア filed Critical ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア
Publication of JP2006500958A publication Critical patent/JP2006500958A/ja
Publication of JP2006500958A5 publication Critical patent/JP2006500958A5/ja
Application granted granted Critical
Publication of JP4717633B2 publication Critical patent/JP4717633B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2005501198A 2002-08-21 2003-08-21 癌関連タンパク質を標的とするＲＮＡｉプローブ Expired - Fee Related JP4717633B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US40519302P 2002-08-21 2002-08-21
US60/405,193 2002-08-21
US40815202P 2002-09-03 2002-09-03
US60/408,152 2002-09-03
US47238703P 2003-05-20 2003-05-20
US60/472,387 2003-05-20
PCT/CA2003/001277 WO2004018676A2 (en) 2002-08-21 2003-08-21 Rnai probes targeting cancer-related proteins

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2010128382A Division JP5171887B2 (ja) 2002-08-21 2010-06-04 癌関連タンパク質を標的とするＲＮＡｉプローブ
JP2010250838A Division JP5662766B2 (ja) 2002-08-21 2010-11-09 癌関連タンパク質を標的とするＲＮＡｉプローブ

Publications (3)

Publication Number Publication Date
JP2006500958A JP2006500958A (ja) 2006-01-12
JP2006500958A5 JP2006500958A5 (enExample) 2006-09-07
JP4717633B2 true JP4717633B2 (ja) 2011-07-06

Family

ID=31950539

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2005501198A Expired - Fee Related JP4717633B2 (ja) 2002-08-21 2003-08-21 癌関連タンパク質を標的とするＲＮＡｉプローブ
JP2010128382A Expired - Fee Related JP5171887B2 (ja) 2002-08-21 2010-06-04 癌関連タンパク質を標的とするＲＮＡｉプローブ
JP2010250838A Expired - Fee Related JP5662766B2 (ja) 2002-08-21 2010-11-09 癌関連タンパク質を標的とするＲＮＡｉプローブ
JP2013067754A Pending JP2013150624A (ja) 2002-08-21 2013-03-28 癌関連タンパク質を標的とするＲＮＡｉプローブ

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2010128382A Expired - Fee Related JP5171887B2 (ja) 2002-08-21 2010-06-04 癌関連タンパク質を標的とするＲＮＡｉプローブ
JP2010250838A Expired - Fee Related JP5662766B2 (ja) 2002-08-21 2010-11-09 癌関連タンパク質を標的とするＲＮＡｉプローブ
JP2013067754A Pending JP2013150624A (ja) 2002-08-21 2013-03-28 癌関連タンパク質を標的とするＲＮＡｉプローブ

Country Status (10)

Country Link
US (5) US8252918B2 (enExample)
EP (2) EP1532249A2 (enExample)
JP (4) JP4717633B2 (enExample)
KR (3) KR101238701B1 (enExample)
AU (1) AU2003258426B2 (enExample)
CA (2) CA2494766C (enExample)
IL (3) IL166658A (enExample)
NO (2) NO334573B1 (enExample)
NZ (1) NZ552872A (enExample)
WO (1) WO2004018676A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011036267A (ja) * 2002-08-21 2011-02-24 Univ Of British Columbia 癌関連タンパク質を標的とするＲＮＡｉプローブ

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL144975A0 (en) 1999-02-26 2002-06-30 Univ British Columbia A composition containing an antisense oligonucleotide
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
CA2469685C (en) 2002-01-17 2013-03-12 The University Of British Columbia Bispecific antisense oligonucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same
CA2494764C (en) * 2002-08-21 2013-04-23 The University Of British Columbia Treatment of melanoma by reduction in clusterin levels
US7635673B2 (en) 2003-03-25 2009-12-22 The Board Of Trustees Of The University Of Illinois Methods of inhibiting tumor cell proliferation
US20040220131A1 (en) * 2003-04-18 2004-11-04 The University Of British Columbia Method for treatment of cancerous angiogenic disorders
US20050019918A1 (en) * 2003-06-03 2005-01-27 Hidetoshi Sumimoto Treatment of cancer by inhibiting BRAF expression
JP2005013221A (ja) * 2003-06-03 2005-01-20 Keio Gijuku Ｂｒａｆ発現抑制を利用した癌の治療
CN101389345A (zh) * 2004-03-19 2009-03-18 宾州研究基金会 治疗黑素瘤的组合方法和组合物
US8710020B2 (en) * 2004-04-02 2014-04-29 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
EP2298896A1 (en) * 2004-06-22 2011-03-23 The Board of Trustees of the University of Illinois Methods of inhibiting tumor cell proliferation with FOXM1 siRNA
CA3147177A1 (en) * 2004-07-23 2006-02-02 Pacific Edge Limited Urine markers for detection of bladder cancer
WO2006035432A2 (en) * 2004-09-27 2006-04-06 Tel Hashomer Medical Research Infrastructure And Services Ltd. Gene silencing for use in dermatology
DK1814595T3 (da) * 2004-11-23 2014-03-31 Univ British Columbia Behandling af cancer med en kombination af et middel, som forstyrrer EGF-signalvejen og et oligonucleotid, som reducerer clusterinniveauerne
US8044179B2 (en) 2005-09-13 2011-10-25 National Research Council Of Canada Methods and compositions for modulating tumor cell activity
US8029980B2 (en) 2006-09-29 2011-10-04 The Board Of Trustees Of The University Of Illinois Identification and use of agents that modulate oncogenic transcription agent activity
WO2008088836A2 (en) * 2007-01-16 2008-07-24 The Burnham Institute For Medical Research Compositions and methods for treatment of colorectal cancer
US8071752B2 (en) 2007-01-29 2011-12-06 City Of Hope Multi-targeting short interfering RNAs
US20100112687A1 (en) * 2007-03-02 2010-05-06 Mdrna, Inc. Nucleic acid compounds for inhibiting erbb family gene expression and uses thereof
US8217161B2 (en) * 2008-04-22 2012-07-10 Clemson University Research Foundation Methods of inhibiting multiple cytochrome P450 genes with siRNA
ES2734886T3 (es) 2009-11-24 2019-12-12 Alethia Biotherapeutics Inc Anticuerpos anti-clusterina y fragmentos de unión a antígeno y su uso para reducir el volumen tumoral
DK2673363T3 (da) 2011-02-11 2017-11-13 Univ Rockefeller Behandling af angiogenesesygdomme
NZ626742A (en) 2012-02-22 2016-06-24 Alethia Biotherapeutics Inc Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer
CA2844640A1 (en) 2013-12-06 2015-06-06 The University Of British Columbia Method for treatment of castration-resistant prostate cancer
CN106282185B (zh) * 2016-08-18 2020-06-26 广州市锐博生物科技有限公司 一种用于抑制簇集蛋白基因表达的成套siRNA及其应用
WO2024214933A1 (ko) * 2023-04-13 2024-10-17 한양대학교 에리카산학협력단 인산화된 igfbp5의 과도한 생성을 차단하여 암을 예방 또는 치료하는 방법
WO2025041340A1 (ja) * 2023-08-24 2025-02-27 株式会社Dti 二重特異性核酸

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5736580A (en) * 1980-08-13 1982-02-27 Hitachi Ltd Protecting method for converter
EP0575518A1 (en) * 1991-03-06 1993-12-29 Board Of Regents, The University Of Texas System Methods and compositions for the selective inhibition of gene expression
AUPM672594A0 (en) * 1994-07-08 1994-08-04 Royal Children's Hospital Research Foundation A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
US20020086386A1 (en) * 1997-03-04 2002-07-04 Kamb Carl Alexander B-catenin assays, and compositions therefrom
US6383808B1 (en) * 2000-09-11 2002-05-07 Isis Pharmaceuticals, Inc. Antisense inhibition of clusterin expression
IL144975A0 (en) 1999-02-26 2002-06-30 Univ British Columbia A composition containing an antisense oligonucleotide
WO2000069454A1 (en) 1999-05-17 2000-11-23 Board Of Regents, The University Of Texas System Suppression of endogenous igfbp-2 to inhibit cancer
ATE393220T1 (de) * 1999-07-19 2008-05-15 Univ British Columbia Antisense-therapie für hormonregulierte tumoren
US6140126A (en) * 1999-10-26 2000-10-31 Isis Pharmaceuticals Inc. Antisense modulation of Y-box binding protein 1 expression
GB9927444D0 (en) * 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
WO2002081628A2 (en) * 2001-04-05 2002-10-17 Ribozyme Pharmaceuticals, Incorporated Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
CA2403397A1 (en) * 2000-03-16 2001-09-20 Genetica, Inc. Methods and compositions for rna interference
DK2796553T3 (da) * 2000-03-30 2019-09-30 Whitehead Inst Biomedical Res Rna-sekvensspecifikke formidlere af rna-interferens
HU229207B1 (en) * 2000-09-14 2013-09-30 Univ British Columbia Antisense insulin-like growth factor binding protein (igfbp)-2-oligodeoxynucleotides for prostate and other endocrine regulated tumor therapy
CZ302719B6 (cs) * 2000-12-01 2011-09-21 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití
EP1354038A2 (en) 2000-12-28 2003-10-22 J & J Research Pty Ltd Double-stranded rna-mediated gene suppression
CA2469685C (en) * 2002-01-17 2013-03-12 The University Of British Columbia Bispecific antisense oligonucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same
KR101238701B1 (ko) * 2002-08-21 2013-03-05 더 유니버시티 오브 브리티쉬 콜롬비아 암-관련 단백질을 표적으로 하는 알엔에이아이 프로브
CA2494764C (en) * 2002-08-21 2013-04-23 The University Of British Columbia Treatment of melanoma by reduction in clusterin levels
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
EP1560931B1 (en) * 2002-11-14 2011-07-27 Dharmacon, Inc. Functional and hyperfunctional sirna

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011036267A (ja) * 2002-08-21 2011-02-24 Univ Of British Columbia 癌関連タンパク質を標的とするＲＮＡｉプローブ

Also Published As

Publication number Publication date
US20040096882A1 (en) 2004-05-20
KR20050042483A (ko) 2005-05-09
NO334573B1 (no) 2014-04-14
IL166658A0 (en) 2006-01-15
EP1532249A2 (en) 2005-05-25
IL166658A (en) 2014-11-30
KR20100135335A (ko) 2010-12-24
US8759308B2 (en) 2014-06-24
IL233352A0 (en) 2014-08-31
JP5662766B2 (ja) 2015-02-04
NO337130B1 (no) 2016-01-25
US20120202873A1 (en) 2012-08-09
US20110009472A1 (en) 2011-01-13
EP2263679A2 (en) 2010-12-22
NZ552872A (en) 2007-11-30
IL197159A0 (en) 2011-07-31
US7964717B2 (en) 2011-06-21
US9487777B2 (en) 2016-11-08
EP2263679B1 (en) 2014-10-08
KR101212512B1 (ko) 2012-12-26
IL197159A (en) 2016-11-30
JP2013150624A (ja) 2013-08-08
EP2263679A3 (en) 2011-10-12
CA2494766A1 (en) 2004-03-04
CA2494766C (en) 2015-05-12
AU2003258426B2 (en) 2008-04-10
JP2011036267A (ja) 2011-02-24
US20080274996A1 (en) 2008-11-06
US8252918B2 (en) 2012-08-28
KR20110122883A (ko) 2011-11-11
KR101238701B1 (ko) 2013-03-05
CA2882443A1 (en) 2004-03-04
CA2882443C (en) 2016-12-13
US20060178329A1 (en) 2006-08-10
JP5171887B2 (ja) 2013-03-27
NO20051423L (no) 2005-05-20
JP2006500958A (ja) 2006-01-12
AU2003258426A1 (en) 2004-03-11
KR101117673B1 (ko) 2012-03-07
US7820635B2 (en) 2010-10-26
WO2004018676A3 (en) 2004-08-12
NO20121038L (no) 2005-05-20
WO2004018676A2 (en) 2004-03-04
JP2010193908A (ja) 2010-09-09

Similar Documents

Publication Publication Date Title
JP5171887B2 (ja) 癌関連タンパク質を標的とするＲＮＡｉプローブ
JP5841332B2 (ja) 細胞増殖阻害剤
CA3161513A1 (en) Antisense oligonucleotide targeting linc00518 for treating melanoma
AU2007216630B2 (en) RNAi probes targeting cancer-related proteins
NZ538287A (en) RNAi probes targeting cancer-related proteins
CA2680058C (en) Induction of apoptosis and inhibition of cell proliferation through modulation of carnitine palmitoyltransferase 1c activity
US20170044548A1 (en) Methods and compositions for the treatment of cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060721

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060721

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090602

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090831

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100604

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20101110

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20101202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110207

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110308

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110330

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140408

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees